Overview

A Study of AK0529 in Infants Hospitalized With RSV

Status:
Terminated
Trial end date:
2015-11-03
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single dose of AK0529 in infants hospitalized with respiratory syncytial virus (RSV).
Phase:
Phase 1
Details
Lead Sponsor:
Ark Biosciences Inc.
Treatments:
Ziresovir